Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-12-21
Based on 459 first isolates · GER · Febrile UTI / pyelonephritis · 2024-12-22 → 2025-12-21
Geriatrics
Per-organism detail: GER urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
meropenem 83 % (80 %–87 %)
Carbapenem: reserve for ESBL / critically ill patients.
Not covered: Enterococcus faecalis (11 %), Staphylococcus saprophyticus (2 %), Staphylococcus aureus (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli not for this site
84 %
94 %
n = 31
meropenem MEM
trend · Escherichia coli reserve
83 %
74 %
n = 31
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
80 %
71 %
n = 31
mecillinam MEC
trend · Escherichia coli not for this site
77 %
68 %
n = 31
ceftriaxone CRO
trend · Escherichia coli
76 %
61 %
n = 31
ciprofloxacin CIP
trend · Escherichia coli
76 %
74 %
n = 31
72 %
58 %
n = 31
trimethoprim TMP
trend · Escherichia coli not for this site
68 %
68 %
n = 31
52 %
52 %
n = 31
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
14 %
26 %
n = 31
4 %
6 %
n = 31
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
2 %
6 %
n = 31

Most likely organisms for this profile

Escherichia coli
57 %
Enterococcus faecalis
11 %
Klebsiella pneumoniae
9 %
Proteus mirabilis
8 %
Citrobacter freundii
4 %
Pseudomonas aeruginosa
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.